Meliglix 25 Mg (Sitagliptin)

Sitagliptin blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, sitagliptin enhances glucose‑dependent insulin secretion, reduces glucagon release, and helps lower blood glucose levels after meals.

The prescribed dose of Meliglix is determined by the treating physician based on individual patient factors. In many regions, a common starting dose is 25 mg taken once daily, but the exact regimen should follow the prescriber’s instructions.

Safety of sitagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Meliglix product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meliglix (sitagliptin) belongs to the DPP‑4 inhibitor class, offering glucose‑dependent insulin release with a low risk of hypoglycaemia compared with sulfonylureas. Unlike metformin, it does not affect gastrointestinal absorption, and it can be combined with many other antidiabetic agents for additive effect.

Store Meliglix tablets at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid exposure to excessive heat or humidity.

Meliglix is taken orally as a tablet, usually once daily. It may be swallowed with or without food, according to the prescribing clinician’s guidance. Consistency in the timing of each dose helps maintain stable blood levels.

Serious adverse events to monitor include pancreatitis, severe allergic reactions such as angioedema or anaphylaxis, and unexplained joint pain. Patients should seek immediate medical attention if they experience persistent abdominal pain, swelling of the face or throat, or severe musculoskeletal discomfort.

Meliglix should be avoided in individuals with known hypersensitivity to sitagliptin or any component of the formulation. It is also contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) unless dose adjustments are made, and in those with a history of pancreatitis.